Pricing and patient acceptance of Seleniso in China

The price of Selinexor in the Chinese market has attracted much attention. Due to regional differences, supply chain changes and fluctuations in market demand, the selling price of Seleniso is not static. From production to sales, every step may have an impact on the final price. As an oral selective nuclear transport inhibitor, selinesol precisely inhibits the function of Karyopherin β1 protein and blocks the transport process of key proteins in cancer cells, thus weakening the viability of cancer cells. It has shown significant efficacy in the treatment of malignant hematological tumors such as multiple myeloma and diffuse large B-cell lymphoma, providing new treatment options for these patients.

For most patients, drug price is undoubtedly an important consideration in treatment decisions. At present, the original drug Seleniso has been launched in China and has been included in the scope of medical insurance, which undoubtedly reduces the financial burden on patients. It is understood that the price of each box of selinesol is approximately more than 20,000 yuan. For patients who meet the indications, the actual payment can be reduced through medical insurance reimbursement. However, even with the support of medical insurance reimbursement, patient acceptance of drug prices is still a complex issue. Different patients' financial circumstances, disease severity, and expectations about treatment effectiveness all influence their perceptions of drug prices.

In general, Seleniso’s pricing in China is the result of a comprehensive consideration of many factors. When formulating a treatment plan, in addition to considering the efficacy and safety of the drug, doctors also need to fully understand the patient's financial affordability to ensure the feasibility of the treatment plan and the patient's compliance.